Literature DB >> 20687495

Clinical features and molecular mechanisms of spinal and bulbar muscular atrophy (SBMA).

Masahisa Katsuno1, Haruhiko Banno, Keisuke Suzuki, Hiroaki Adachi, Fumiaki Tanaka, Gen Sobue.   

Abstract

Spinal and bulbar muscular atrophy (SBMA) is an adult-onset neurodegenerative disease characterized by slowly progressive muscle weakness and atrophy. The cause of this disease is the expansion of a trinucleotide CAG repeat, which encodes the polyglutamine tract, within the first exon of the androgen receptor (AR) gene. SBMA exclusively occurs in adult males, whereas both heterozygous and homozygous females are usually asymptomatic. Lower motor neurons in the anterior horn of the spinal cord and those in the brainstem motor nuclei are predominantly affected in SBMA, and other neuronal and nonneuronal tissues are also widely involved to some extent. Testosterone-dependent nuclear accumulation of the pathogenic AR protein has been considered to be a fundamental step of neurodegenerative process, which is followed by several molecular events such as transcriptional dysregulation, axonal transport disruption and mitochondrial dysfunction. Results of animal studies suggest that androgen deprivation and activation of protein quality control systems are potential therapies for SBMA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20687495     DOI: 10.1007/978-1-4419-6448-9_6

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  14 in total

1.  [Motor neuron diseases].

Authors:  S Petri; T Meyer
Journal:  Nervenarzt       Date:  2011-06       Impact factor: 1.214

2.  Brain MR diffusion tensor imaging in Kennedy's disease.

Authors:  Francesco Garaci; Nicola Toschi; Simona Lanzafame; Girolama A Marfia; Simone Marziali; Alessandro Meschini; Francesca Di Giuliano; Giovanni Simonetti; Maria Guerrisi; Roberto Massa; Roberto Floris
Journal:  Neuroradiol J       Date:  2015-05-11

Review 3.  The Role of Sex and Sex Hormones in Neurodegenerative Diseases.

Authors:  Elisabetta Vegeto; Alessandro Villa; Sara Della Torre; Valeria Crippa; Paola Rusmini; Riccardo Cristofani; Mariarita Galbiati; Adriana Maggi; Angelo Poletti
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

Review 4.  CUG-BP, Elav-like family (CELF)-mediated alternative splicing regulation in the brain during health and disease.

Authors:  Andrea N Ladd
Journal:  Mol Cell Neurosci       Date:  2012-12-14       Impact factor: 4.314

5.  Sleep disorders in spinal and bulbar muscular atrophy (Kennedy's disease): a controlled polysomnographic and self-reported questionnaires study.

Authors:  Andrea Romigi; Claudio Liguori; Fabio Placidi; Maria Albanese; Francesca Izzi; Elisabetta Uasone; Chiara Terracciano; Maria Grazia Marciani; Nicola Biagio Mercuri; Raffaella Ludovisi; Roberto Massa
Journal:  J Neurol       Date:  2014-03-04       Impact factor: 4.849

Review 6.  Inhibition of the Androgen Receptor by Antiandrogens in Spinobulbar Muscle Atrophy.

Authors:  Aria Baniahmad
Journal:  J Mol Neurosci       Date:  2015-11-12       Impact factor: 3.444

Review 7.  New routes to therapy for spinal and bulbar muscular atrophy.

Authors:  Anna Rocchi; Maria Pennuto
Journal:  J Mol Neurosci       Date:  2013-02-19       Impact factor: 3.444

8.  Small-molecule hormones: molecular mechanisms of action.

Authors:  Monika Puzianowska-Kuznicka; Eliza Pawlik-Pachucka; Magdalena Owczarz; Monika Budzińska; Jacek Polosak
Journal:  Int J Endocrinol       Date:  2013-02-28       Impact factor: 3.257

9.  Mechanisms mediating spinal and bulbar muscular atrophy: investigations into polyglutamine-expanded androgen receptor function and dysfunction.

Authors:  Lenore K Beitel; Carlos Alvarado; Shaza Mokhtar; Miltiadis Paliouras; Mark Trifiro
Journal:  Front Neurol       Date:  2013-05-15       Impact factor: 4.003

10.  Androgen receptor polyglutamine repeat number: models of selection and disease susceptibility.

Authors:  Calen P Ryan; Bernard J Crespi
Journal:  Evol Appl       Date:  2012-06-11       Impact factor: 5.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.